Pioneering the Future
The content on this website is for informational purposes only and is not intended for patient use or as medical advice, diagnosis, or treatment recommendations. These services cannot be ordered directly by patients. Test orders and clinical decisions should only be made by a licensed healthcare provider.
NIMA’s services are intended solely for healthcare professionals, and any decisions regarding the use of these services should be made in consultation with a qualified physician. No medical diagnosis or treatment decisions should be based solely on the information provided on this website.The information provided here is a partial overview and should not be considered a full product description. For comprehensive details, including consent forms and other official communications, please consult your physician.
No medical diagnosis or treatment should be based solely on the information from this website. It does not create a physician-patient relationship. The provider is not liable for any decisions or actions based on this website’s content. All test orders must be made in accordance with applicable laws and medical guidelines, and under the supervision of a licensed healthcare provider.
Empowering Embryo Selection with Advanced Non-Invasive Genomic, AI, and Metabolomic Testing
At Fertinom, we are revolutionizing the field of reproductive genetics by introducing innovative, non-invasive approaches to embryo selection that preserve embryo integrity while enhancing assessment accuracy. Through the integration of advanced metabolomic analysis, non-invasive genomic testing, and AI, we provide a holistic, comprehensive evaluation of embryo health. Our mission is to elevate clinical outcomes by offering a safer, more precise alternative to traditional biopsy-based methods, especially in regions where such procedures are not commonly available. By harnessing these cutting-edge technologies, we aim to increase the chances of successful pregnancies, reduce the risk of miscarriage, and make life-changing reproductive services more accessible to patients worldwide.
Why Choose Fertinom?
Limitations of Traditional PGTA and Biopsy-Based Testing
While PGTA offers valuable insights into chromosomal health, it only captures part of the picture, it does not evaluate the full biological or metabolic fitness of an embryo, which are critical factors for long-term success. In contrast, Fertinom’s multi-faceted approach, which integrates genomic, metabolic, imaging, and AI, provides a more complete picture of embryo health. By incorporating metabolic assessment alongside genomics, we ensure a more holistic and reliable evaluation that better predicts the embryo’s potential for success, reducing the risks associated with traditional biopsy-based methods.
Preserving Embryo Integrity: Traditional biopsy techniques can damage embryos when not handled properly, potentially affecting their. Non-invasive PGTA eliminates this risk, ensuring that embryos remain unharmed and their potential for success is preserved.
Cost-Effective AND Global Accessibility: Non-invasive testing significantly reduces the cost associated with embryo biopsy, lowering patient expenses. This makes advanced reproductive care more accessible, particularly in low-resource settings. By removing the cost associated with biopsy procedure, NIMA has made the non-invasive metabolomic platform accessible to patients worldwide, particularly in underserved communities.
How It Works
Discover how Fertinom has made a positive impact on the lives of our patients. Read real stories from individuals who have experienced improved health.
NIMA’s Metabolomic Analysis and Machine Learning Integration
NIMA utilizes mass spectrometry and machine learning algorithms to analyze the complex metabolic profiles in embryo culture media, identifying patterns associated with positive clinical outcomes. Metabolomics provides a unique perspective into the embryo’s biology, reflecting its metabolic health. Additionally, AI-driven image analysis can be employed to assess embryo morphology, offering further insights into embryo development potential. When requested, Non-invasive aneuploidy screening can complement these analyses by evaluating chromosome copy number and genetic integrity. The integration of these diverse data streams is processed through sophisticated algorithms, delivering a complete evaluation of embryo health.
Holistic NIMA Approach vs. Non-Invasive and Biopsy-Based Preimplantation Genetic Testing
Current biopsy-based preimplantation genetic testing, although essential for assessing chromosomal anomalies, has its own limitations. PGT primarily focuses on detecting aneuploidies associated with implantation failure, miscarriage, and genetic syndromes. However, it does not evaluate the biological or metabolic fitness of embryos, which is crucial for determining their overall viability. Additionally, the invasive nature of biopsy procedures can damage embryos, impacting the clinical outcome.
In contrast, Fertinom’s holistic approach integrates metabolomics, genomics, imaging, and AI, providing a more comprehensive assessment of embryo viability. This multi-dimensional strategy addresses the limitations of both current non-invasive and biopsy-based preimplantation genetic testing.
What We Offer
NIMA: Non-Invasive Metabolomic Assessment
NIMA is an advanced, holistic embryo assessment platform designed to enhance the process of preimplantation evaluation. By integrating cutting-edge technologies such as metabolomics, genomics, AI-driven imaging, and machine learning, NIMA provides a comprehensive analysis of embryo viability. This multi-dimensional approach goes beyond traditional testing methods, offering deeper insights into both the metabolic and genomic health of embryos. NIMA’s non-invasive nature avoids the potential harms of invasive biopsy procedures, ensuring safer, more reliable evaluations. NIMA can be offered as a basic metabolomic test or in combination with genomics and image assessments. For more information, please contact our support team.
Improved Implantation and Pregnancy Success: Metabolomic profiling analyzes the metabolites produced by embryos, offering a unique window into their metabolic health. This deep biological insight helps clinicians identify embryos with the highest potential for successful implantation, significantly reducing the risk of miscarriage and improving overall pregnancy outcomes.
Beyond Chromosomal Health – The Biology of the Embryo: While PGTA primarily focuses on chromosome number, it doesn’t fully account for an embryo’s metabolic potential or its ability to thrive once implanted. By integrating metabolomics with genomic and imaging data, we gain a more complete picture of embryo viability, enhancing the selection process for the most biologically fit embryos.
Reducing the Need for Invasive Biopsies: With the power of metabolomics, clinicians can make more informed decisions about embryo selection without relying solely on invasive biopsy procedures. This comprehensive approach reduces the need for physical intervention, offering a safer, non-invasive alternative for both embryos and patients.
Our Mission
Our mission at Fertinom is to revolutionize reproductive health by leveraging the latest in genomics, metabolomics, and AI technologies to enhance the embryo selection process, promoting both the safety and integrity of embryos. By offering non-invasive embryo screening, we aim to improve clinical outcomes, reduce risks, and increase accessibility to high-quality reproductive care, particularly in regions where biopsy is not a common practice.
Who We Are
Fertinom is led by a team of experienced pioneers in reproductive genetics, mass spectrometry, clinical genomics, and embryology. Our multidisciplinary team of reproductive geneticists, scientists, technology experts, and clinicians brings decades of expertise to advancing reproductive care. We are united by a shared passion for delivering innovative, patient-centered solutions that address the critical challenges in assisted reproduction. By combining cutting-edge technology with clinical expertise, we aim to redefine the standards of care, providing safer, more effective, and accessible options for patients worldwide.
Contact Us Today
Interested in learning more or scheduling a consultation? Our team is ready to answer your questions and help guide you through the process.
- Information
- support@fertinom.com
- +1 (858) 257-2122
FAQ
Explore our FAQ section to find answers to your pressing questions about fertility treatments.
01What is Non-Invasive PGTA?
Non-Invasive PGTA uses advanced genomic technologies to assess the viability of embryos without the need for a biopsy, reducing risks and making the process more accessible.
02How does Metabolomic Profiling work?
Non-Invasive PGTA uses advanced genomic technologies to assess the viability of embryos without the need for a biopsy, reducing risks and making the process more accessible.
03What makes Fertinom different from other labs?
Non-Invasive PGTA uses advanced genomic technologies to assess the viability of embryos without the need for a biopsy, reducing risks and making the process more accessible.